| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Congenital diaphragmatic hernia (CDH) is a disease that has a still high mortality rate among neonatal surgical diseases. In our facility, intensive care based on gentle vetilation gained marked improvement in survival rate. However, patients who have severe pulmonary hypoplasia can not be rescued. In order to develop fetal therapy for severe cases, administration of neuropeptide bombesin to congenital diaphragmatic hernia model rat increased lung body weight ratio, decreased cell growth factor, type 2 alveolar epithelial cells Results leading to lung maturation such as reduction could be obtained. As for the effect of combined use with other drugs, it is impossible to obtain sufficient results and it is a future subject.
|
